Fidelity Management & Research Co.. recently announced the acquisition of new stake in BioNTech SE (NASDAQ:BNTX). The institutional investor has increased its shareholding in the Healthcare company by 1,338.63% to 10.19 million shares with purchase of 9.49 million shares. This fresh investment now brings its stake to 4.28% valued currently at $837.05 million. In addition, Redmile Group LLC raised its holdings by 2.9 million to 3.07 million shares. And PRIMECAP Management Co. has lifted its position by 6.15% or 0.16 million shares – to 2.77 million shares.

With over 1.76 million BioNTech SE (BNTX) shares trading Friday and a closing price of $64.00 on the day, the dollar volume was approximately $112.51 million. The shares have shown a negative weekly performance of -12.35% and its price on 08/28/20 lost nearly -2.42%. Currently, there are 232.36M common shares owned by the public and among those 220.45M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 10 analysts who have offered their price forecasts for BNTX have a consensus price objective of $75.46. The analysts have set the share’s price value over the next 12 months at a high of $100.00 and a low of $28.00 should the stock experience a downside. Incidentally, analysts’ outlook for the BioNTech SE stock is 2.30 for the next 12 months. The average price target is 16.87% above its last price level and an upside to the estimated low will see the stock lose -128.57% over that period. But an upside of 36.0% will see the stock hit the forecast high price target while mean target price for the stock is $70.13.

The top 3 mutual fund holders in BioNTech SE are Fidelity Growth Company Fund, PRIMECAP Odyssey Aggressive Growt, and Vanguard Capital Opportunity Fund. Fidelity Growth Company Fund owns 2.87 million shares of the company’s stock, all valued at over $235.5 million. The company sold 56861.0 shares recently to bring their total holdings to about 1.20% of the shares outstanding. PRIMECAP Odyssey Aggressive Growt bought 5042.0 shares to see its total holdings expand to 1.36 million shares valued at over $111.98 million and representing 0.57% of the shares outstanding. Vanguard Capital Opportunity Fund bought 65733.0 shares to bring its total holdings to over 1.21 million shares at a value of $99.64 million. Vanguard Capital Opportunity Fund now owns shares totaling to 0.51% of the shares outstanding.

Shares of BioNTech SE (NASDAQ: BNTX) opened at $65.04, down -$0.55 from a prior closing price of $65.59. However, the script later closed the day at $64.00, down -2.42%. The company’s stock has a 5-day price change of -12.35% and 22.37% over the past three months. It has a 12-month low price of $12.52 and touched a high of $105.00 over the same period. Currently, 1.76 million shares have been traded, compared to an average intraday trading volume of 3.17 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -12.04%, -12.05%, and 33.71% respectively.

Institutional ownership of BioNTech SE (NASDAQ: BNTX) shares accounts for 11.40% of the company’s 232.36M shares outstanding. Mutual fund holders own 5.57%, while other institutional holders and individual stakeholders account for 5.77% and — respectively.

It has a market capitalization of $15.62B. The earnings-per-share (ttm) stands at -$1.21. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.64% over the week and 6.23% over the month.

Analysts forecast that BioNTech SE (BNTX) will achieve an EPS of -$0.41 for the current quarter, $0.77 for the next quarter and $7.33 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.58 while analysts give the company a high EPS estimate of -$0.2. Comparatively, EPS for the current quarter was -$0.14 a year ago. Earnings per share for the fiscal year are expected to decrease by -300.50%, and 2125.00% over the next financial year.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 10 brokerage firm advisors rate BioNTech SE (BNTX) as a “Moderate Buy” at a consensus score of 2.30. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 6 of the 10 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the BNTX, a number of firms have released research notes about the stock. Berenberg stated their Buy rating for the stock in a research note on August 03, 2020, with the firm’s price target at $98. BofA Securities coverage for the BioNTech SE (BNTX) stock in a research note released on July 21, 2020 offered a Buy rating with a price target of $105. H.C. Wainwright was of a view on June 30, 2020 that the stock is Neutral, while H.C. Wainwright gave the stock Buy rating on May 19, 2020, issuing a price target of $48- $69. BofA/Merrill on their part issued Neutral rating on April 28, 2020.